Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

DOI

  • J F Schwensen, Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark; and.
  • ,
  • A Clemmensen, Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark; and.
  • ,
  • C Sand
  • R Gniadecki, Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark; and.
  • ,
  • L Skov, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
  • ,
  • C Zachariae, Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
  • ,
  • L Iversen
  • Mads Rasmussen
  • ,
  • S F Thomsen, Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark; and., j Department of Biomedical Sciences , University of Copenhagen , Copenhagen , Denmark.

Secukinumab (anti-IL17A) is effective as treatment for moderate to severe plaque psoriasis, but real-life data on effectiveness and safety lack. We aimed to present real-life data of all Danish patients treated with secukinumab (n = 69). At baseline, before initiation of treatment with secukinumab 300 mg (47.8%) or off-label treatment with secukinumab 150 mg (52.2%), the median PASI score was 7.1. A total of 66.7% (34/51) and 52.9% (27/51) of patients still on secukinumab at week 12 achieved a PASI (Psoriasis Area and Severity Index)-50 and PASI-75 of 66.7% and 52.9%, respectively. A total of 83.0% (44/53) and 60.4% (32/53) of the patients had a PASI-score < 5 and PASI-score < 2, respectively, after 12 weeks on treatment with secukinumab. A third of the patients had secukinumab discontinued due to limited clinical improvement or adverse events (n = 23) within a median of 92 days (interquartile range 51-212 days). Notably, the majority of the patients may represent a particularly difficult-to-treat group of patients, as 92.8% had been refractory to other biologic treatment. A total of 26.1% (n = 18) experienced adverse events. Secukinumab appears to be an effective treatment option with a favorable side effect profile in patients with plaque psoriasis who are refractory to or have side effects of traditional biologic drugs.

Original languageEnglish
Article numberdoi: 10.1111/dth.12550
JournalDermatology and therapy
ISSN2193-8210
DOIs
Publication statusPublished - Nov 2017

    Research areas

  • Journal Article

See relations at Aarhus University Citationformats

ID: 117251940